Multigenic panels in breast cancer: clinical utility and management of patients with pathogenic variants other than BRCA1/2

IF 5.5 2区 医学 Q1 HEMATOLOGY
Alessandra Fabi , Laura Cortesi , Simona Duranti , Emanuela Lucci Cordisco , Alba Di Leone , Daniela Terribile , Ida Paris , Antonio Giulio de Belvis , Armando Orlandi , Fabio Marazzi , Margherita Muratore , Giorgia Garganese , Paola Fuso , Filippo Paoletti , Rossella Dell’Aquila , Angelo Minucci , Giovanni Scambia , G. Franceschini , R. Masetti , Maurizio Genuardi
{"title":"Multigenic panels in breast cancer: clinical utility and management of patients with pathogenic variants other than BRCA1/2","authors":"Alessandra Fabi ,&nbsp;Laura Cortesi ,&nbsp;Simona Duranti ,&nbsp;Emanuela Lucci Cordisco ,&nbsp;Alba Di Leone ,&nbsp;Daniela Terribile ,&nbsp;Ida Paris ,&nbsp;Antonio Giulio de Belvis ,&nbsp;Armando Orlandi ,&nbsp;Fabio Marazzi ,&nbsp;Margherita Muratore ,&nbsp;Giorgia Garganese ,&nbsp;Paola Fuso ,&nbsp;Filippo Paoletti ,&nbsp;Rossella Dell’Aquila ,&nbsp;Angelo Minucci ,&nbsp;Giovanni Scambia ,&nbsp;G. Franceschini ,&nbsp;R. Masetti ,&nbsp;Maurizio Genuardi","doi":"10.1016/j.critrevonc.2024.104431","DOIUrl":null,"url":null,"abstract":"<div><p>Multigene panels can analyze high and moderate/intermediate penetrance genes that predispose to breast cancer (BC), providing an opportunity to identify at-risk individuals within affected families. However, considering the complexity of different pathogenic variants and correlated clinical manifestations, a multidisciplinary team is needed to effectively manage BC. A classification of pathogenic variants included in multigene panels was presented in this narrative review to evaluate their clinical utility in BC. Clinical management was discussed for each category and focused on BC, including available evidence regarding the multidisciplinary and integrated management of patients with BC. The integration of both genetic testing and counseling is required for customized decisions in therapeutic strategies and preventative initiatives, as well as for a defined multidisciplinary approach, considering the continuous evolution of guidelines and research in the field.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824001744","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Multigene panels can analyze high and moderate/intermediate penetrance genes that predispose to breast cancer (BC), providing an opportunity to identify at-risk individuals within affected families. However, considering the complexity of different pathogenic variants and correlated clinical manifestations, a multidisciplinary team is needed to effectively manage BC. A classification of pathogenic variants included in multigene panels was presented in this narrative review to evaluate their clinical utility in BC. Clinical management was discussed for each category and focused on BC, including available evidence regarding the multidisciplinary and integrated management of patients with BC. The integration of both genetic testing and counseling is required for customized decisions in therapeutic strategies and preventative initiatives, as well as for a defined multidisciplinary approach, considering the continuous evolution of guidelines and research in the field.

Abstract Image

乳腺癌的多基因检测:BRCA1/2 以外致病变异患者的临床实用性和管理。
多基因面板可分析易患乳腺癌(BC)的高、中/中等渗透性基因,为在受影响的家族中识别高危个体提供了机会。然而,考虑到不同致病变异和相关临床表现的复杂性,需要一个多学科团队来有效管理乳腺癌。本综述对多基因面板中的致病变异进行了分类,以评估它们在 BC 中的临床效用。对每个类别的临床管理进行了讨论,并重点关注BC,包括有关BC患者多学科综合管理的现有证据。考虑到该领域指南和研究的不断发展,需要将基因检测和咨询结合起来,以便在治疗策略和预防措施方面做出定制化决定,并采取明确的多学科方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.00
自引率
3.20%
发文量
213
审稿时长
55 days
期刊介绍: Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信